Ginkgo Bioworks Holdings, Inc. · NYSE:DNA
Ginkgo Bioworks — Q1 2026 Earnings Presentation
54 slides from Ginkgo Bioworks's earnings presentation, May 7, 2026
Slide 1: Q1 2026 Update & Business Review
May 7, 2026 Business Review Grow with Ginkgo Q1 2026 Update & Q2 2025 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 1
Slide 2: Disclaimer
Disclaimer Property of Ginkgo Bioworks — 2 FORWARD-LOOKING STATEMENTS This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adapta
Slide 3: Introduction
Property of Ginkgo Bioworks — 3 Introduction Jason Kelly, Co-Founder and CEO Q4 2025 Financial Update Steve Coen, CFO Agenda Q1 2026 UPDATE & BUSINESS REVIEW Strategic Review Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Daniel Marshall, Sr. Manager of Communications and Ownership
Slide 4: Our Mission
Property of Ginkgo Bioworks — 4 OUR MISSION Make biology easier to engineer IN 2026 GINKGO WILL FOCUS AND INVEST TO WIN AUTONOMOUS LABS Focus Ginkgo's efforts on Autonomous Labs as the common platform for biotechnology research. Invest to extend our current progress Q1 2026 UPDATE & BUSINESS REVIEW i
Slide 5: Good luck Perimeter!
Good luck Perimeter! Property of Ginkgo Bioworks — 5 Biosecurity Divestiture closed on April 3, 2026. Q1 2026 UPDATE & BUSINESS REVIEW
Slide 6: Our improved cash burn allows us to invest in winning Autonomous Labs
Our improved cash burn allows us to invest in winning Property of Ginkgo Bioworks — 6 Autonomous Labs (Unaudited) ANNUAL CASH BURN(1) ($M) $373M Ginkgo remains in a strong financial position Q1 2026 UPDATE & BUSINESS REVIEW with $373 million in cash, cash equivalents, $150 and marketable securities w
Slide 7: Introduction
Property of Ginkgo Bioworks — 7 Introduction Jason Kelly, Co-Founder and CEO Q1 2026 Financial Update Steve Coen, CFO Agenda Q1 2026 UPDATE & BUSINESS REVIEW Strategic Review Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Daniel Marshall, Sr. Manager of Communications and Ownership
Slide 8: Q1 2026 Financial Summary
Property of Ginkgo Bioworks — 8 Q1 2026 Financial Summary (Unaudited) Three Months Ended March 31, In millions of USD 2026 2025 % YoY Revenue (1) $19 $38 (49%) Costs and operating expenses: Cost of other revenue (2) 3 3 (14%) Research and development (2) 30 49 (38%) General and administrative (2) 13
Slide 9: Ginkgo reaffirms total cash burn guidance
Ginkgo reaffirms total cash burn guidance Property of Ginkgo Bioworks — 9 Historical Outlook In millions of USD FY2025 FY2026 Total cash burn(1) ($171) ($150) - ($125) Q1 2026 UPDATE & BUSINESS REVIEW (1) References to cash burn is defined as change in GAAP cash, cash equivalents, and marketable securi
Slide 10: Introduction
Property of Ginkgo Bioworks — 10 Introduction Jason Kelly, Co-Founder and CEO Q4 2025 Financial Update Steve Coen, CFO Agenda Q1 2026 UPDATE & BUSINESS REVIEW Strategic Review Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Daniel Marshall, Sr. Manager of Communications and Ownership
Slide 11: Our Mission
OUR MISSION Make biology easier to engineer Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 11
Slide 12: We believe…
Property of Ginkgo Bioworks — 12 We believe… 1 2 3 Autonomous labs will Nebula is showing what is Cloud Lab, Datapoints, and replace the bench. possible at the bleeding Solutions are our version edge. of Starlink. Q1 2026 UPDATE & BUSINESS REVIEW 12
Slide 13: We believe…
Property of Ginkgo Bioworks — 13 We believe… 1 2 3 Autonomous labs will Nebula is showing what is Cloud Lab, Datapoints, and replace the bench. possible at the bleeding Solutions are our version edge. of Starlink. Q1 2026 UPDATE & BUSINESS REVIEW 13
Slide 14: Amount of Automation vs Request Flexibility
Amount of Automation Request Flexibility Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 14
Slide 15: Autonomous Car
Amount of Automation Request Flexibility Autonomous Car Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 15
Slide 16: Autonomous Car
Property of Ginkgo Bioworks — 16 Autonomous Car Amount of Q1 2026 UPDATE & BUSINESS REVIEW Automation 99% of transportation! Request Flexibility
Slide 17: Traditional Automation
Property of Ginkgo Bioworks — 17 Traditional Automation Workcell Amount of Q1 2026 UPDATE & BUSINESS REVIEW Automation Request Flexibility
Slide 18: Traditional Automation
Property of Ginkgo Bioworks — 18 Traditional Automation Workcell Amount of Q1 2026 UPDATE & BUSINESS REVIEW Automation 95%+ of research budget! Request Flexibility
Slide 19: Ginkgo Autonomous Lab
Property of Ginkgo Bioworks — 19 Ginkgo Traditional Autonomous Automation Lab Workcell Amount of Q1 2026 UPDATE & BUSINESS REVIEW Automation Request Flexibility
Slide 20: Value proposition today to kill the lab bench
Property of Ginkgo Bioworks — 20 Value proposition today to kill the lab bench: 1. Save massive overhead costs on space by closing or not building traditional lab benches 2. Increase research productivity of your human scientists in an age of AI where we need more data per research $. 3. Enable AI-s
Slide 21: The ROI for an autonomous lab is clear
Property of Ginkgo Bioworks — 21 Traditional Lab Autonomous Lab The ROI for an autonomous lab is clear. Q1 2026 UPDATE & BUSINESS REVIEW Our manual lab used ~3x the space per instrument compared to our autonomous lab. Operational 168 hours a week Operational 40 hours a week. (a 4x improvement). 21
Slide 22: Value is there if we can deliver on the key technical challenge
Property of Ginkgo Bioworks — 22 Value is there if we can deliver on the key technical challenge: How do you get both high automation and high flexibility Q1 2026 UPDATE & BUSINESS REVIEW without human hands in the lab?
Slide 23: Workcells are designed around your workflow / protocol
Property of Ginkgo Bioworks — 23 Workcells are designed around your workflow / protocol because they assume no variability in user requests. Q1 2026 UPDATE & BUSINESS REVIEW Autonomous labs are designed around your equipment because they assume variability equal to a manual lab.
Slide 24: RACs solve the challenges of conventional, inflexible automation systems
RACs solve the challenges of conventional, inflexible Property of Ginkgo Bioworks — 24 automation systems with their unique, modular architecture Optional HEPA Filter Dedicated robotic arm improves reliability and Lab device of choice, from throughput any application or vendor Q1 2026 UPDATE & BUSINE
Slide 25: Q1 2026 Update & Business Review
Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 25
Slide 26: Q1 2026 Update & Business Review
Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 26
Slide 27: RAC Systems Can Scale With Need
Property of Ginkgo Bioworks — 27 RAC Systems Can Scale With Need Linear RAC System (2-5 RACs) Q1 2026 UPDATE & BUSINESS REVIEW Mega RAC “One-of-Everything” Closed Loop RAC System System (10-20 RACs) (100+ RACs)
Slide 28: We believe…
Property of Ginkgo Bioworks — 28 We believe… 1 2 3 Autonomous labs will Nebula is showing what is Cloud Lab, Datapoints, and replace the bench. possible at the bleeding Solutions are our version edge. of Starlink. Q1 2026 UPDATE & BUSINESS REVIEW 28
Slide 29: 100+ protocols submitted by scientists in a single day
Property of Ginkgo Bioworks — 29 100+ protocols (30+ unique) submitted by scientists in a single day running across 50+ lab devices on an integrated automation setup. Q1 2026 UPDATE & BUSINESS REVIEW There is nothing else like Nebula in the world today. It is proof that autonomous labs are feasible.
Slide 30: What it takes to replace the manually-operated lab
Property of Ginkgo Bioworks — 30 What it takes to replace the manually-operated lab 1. Connect 100+ devices in a single automation setup with reliable sample transport and delivery to devices via RAC productized hardware 2. 10s-100s of different protocols must run in parallel on the same autonomous l
Slide 31: Nebula, at our Boston HQ, is expected to grow to 105 RACs
Property of Ginkgo Bioworks — 31 Q1 2026 UPDATE & BUSINESS REVIEW Nebula, at our Boston HQ, is expected to grow from 50 to 105 RACs by the end of this month
Slide 32: Q1 2026 Update & Business Review
Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 32
Slide 33: Q1 2026 Update & Business Review
Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 33
Slide 34: USG policy and investment will also drive towards autonomous labs
USG policy and investment will also drive towards Property of Ginkgo Bioworks — 34 autonomous labs Q2 2025 UPDATE & BUSINESS REVIEW
Slide 35: SOURCES: PNNL + Synbiobeta
SOURCES: PNNL + Synbiobeta Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 35
Slide 36: ARPA-H Gets a Tour of Nebula
ARPA-H Gets a Tour of Nebula Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 36
Slide 37: We are using Nebula to showcase what is possible
Property of Ginkgo Bioworks — 37 We are using Nebula to showcase what is possible – but we are also building autonomous labs for early-adopter customers. Q1 2026 UPDATE & BUSINESS REVIEW
Slide 38: 600+ visitors in Q1
600+ visitors in Q1 Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 38
Slide 39: We believe…
Property of Ginkgo Bioworks — 39 We believe… 1 2 3 Autonomous labs will Nebula is showing what is Cloud Lab, Datapoints, and replace the bench. possible at the bleeding Solutions are our version edge. of Starlink. Q1 2026 UPDATE & BUSINESS REVIEW 39
Slide 40: Every service we do on top of our autonomous lab generates revenue
Property of Ginkgo Bioworks — 40 Every service we do on top of our autonomous lab generates revenue and helps us improve it. Q2 2025 UPDATE & BUSINESS REVIEW
Slide 41: cloud.ginkgo.bio
cloud.ginkgo.bio ~1 new protocol each week Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 41
Slide 42: Science run on our cloud lab is already making headlines
making headlines. Science run on our cloud lab is already Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 42
Slide 43: New channels appearing for cloud lab and datapoints services
New channels appearing for cloud lab and datapoints services Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 43
Slide 44: Datapoints Defined the Category of Bio-AI Data Provider
Property of Ginkgo Bioworks — 44 Datapoints Defined the Category of Bio-AI Data Provider Worked with 10 Top Pharma Customers in Its First Full Year SCALED AUTOMATED WETLAB WORKFLOWS STRONG CUSTOMER DEMAND ACROSS SEGMENTS Omics AbDev ADME Launched in Q4 2024 Generated 100,000+ Antibody datapoints Q1 2
Slide 45: Datapoints is your partner for the Bio x AI era
Property of Ginkgo Bioworks — 45 Datapoints is your partner for the Bio x AI era Antibody Developability Competition Virtual Cell Pharmacology Initiative Datapoints Summit Series Data Drops Q1 2026 UPDATE & BUSINESS REVIEW
Slide 46: Our solutions business spans a huge range of biotech lab work
Property of Ginkgo Bioworks — 46 Our solutions business spans a huge range of biotech lab work PHARMA INDUSTRIAL BIOTECHNOLOGY AGRICULTURE LARGE COMPANIES Q1 2026 UPDATE & BUSINESS REVIEW STARTUPS Note: Logos are customers (shared with permission); this is not an exhaustive list.
Slide 47: Migrating our solutions work to Nebula
Property of Ginkgo Bioworks — 47 Migrating our solutions work from lab benches and walk-up automation to Nebula proves the hardest but biggest market for autonomous labs: replacing the manual lab bench. Q1 2026 UPDATE & BUSINESS REVIEW
Slide 48: Come visit!!!
Come visit!!! https://calendly.com/ginkgo-bio/tour-ginkgo Q1 2026 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 48
Slide 49: Let's grow the world we want to see
Property of Ginkgo Bioworks — 49 ____________________ Let’s grow the world Q1 2026 UPDATE & BUSINESS REVIEW we want to see jason@ginkgobioworks.com
Slide 50: Introduction
Property of Ginkgo Bioworks — 50 Introduction Jason Kelly, Co-Founder and CEO Q3 2025 Financial Update Steve Coen, CFO Agenda Q1 2026 UPDATE & BUSINESS REVIEW Strategic Review Jason Kelly, Co-Founder and CEO Q&A Session Moderated by Daniel Marshall, Sr. Manager of Communications and Ownership
Slide 51: Appendix
APPENDIX Q2 2025 UPDATE & BUSINESS REVIEW Property of Ginkgo Bioworks — 51
Slide 52: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation (Unaudited) Property of Ginkgo Bioworks — 52 Three Months Ended March 31, In millions of USD 2026 2025 Net loss from continuing operations ⁽¹⁾ $ (76.1) $ (83.3) Interest income, net (3.6) (6.1) Income tax (benefit) expense (0.1) 0.1 Depreciation and amortization 12.8 14
Slide 53: Cash Burn Reconciliation
Cash Burn Reconciliation (unaudited) Property of Ginkgo Bioworks — 53 Three Months Ended March 31, In millions of USD 2026 2025 Net decrease in cash, cash equivalents and restricted cash $ (24) $ (250) Net increase (decrease) in marketable securities 25 (191) Cash Flow (49) (59) Q1 2026 UPDATE & BUS
Slide 54: Cash Burn Reconciliation
Cash Burn Reconciliation (unaudited) Property of Ginkgo Bioworks — 54 Twelve Months Ended December 31, In millions of USD 2025 2024 Net decrease in cash, cash equivalents and restricted cash $ (393) $ (383) Net decrease in marketable securities 235 0 Q1 2026 UPDATE & BUSINESS REVIEW Cash Flow (158)
Ginkgo Bioworks Holdings — Q1 2026 Earnings Presentation on 6ix